GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
,_Thyrocare_256_384.jpg)
Dr Kinha is a seasoned healthcare and diagnostics leader with over 17 years of experience across leading organisations in the diagnostics sector, with deep expertise in laboratory operations and quality systems
The move strengthens GBL’s clinical-stage presence in the United States
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Subscribe To Our Newsletter & Stay Updated
